Sign In
Buy OCUP
$1.17
+0 (+0%)
At Close: Jan 22, 2025
Ocuphire Pharma (OCUP) Stock: Why The Price Surged Today
07:58am, Wednesday, 24'th Nov 2021
The stock price of Ocuphire Pharma Inc (NASDAQ: OCUP) increased by over 65% pre-market today. This is why it happened.
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
03:00pm, Thursday, 18'th Nov 2021 Zacks Investment Research
Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:28am, Thursday, 18'th Nov 2021
Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022
New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Ma
FARMINGTON HILLS, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 03'rd Sep 2021
FARMINGTON HILLS, Mich., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely
Ocuphire Pharma Presenting at Two Conferences in August
07:30am, Friday, 06'th Aug 2021
Canaccord Genuity 41 st Annual Growth Conference being held virtually on August 10-12, 2021
Ocuphire Pharma: An Undervalued Ophthalmic Play
04:11pm, Thursday, 05'th Aug 2021
Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications.
Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Dise
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 09'th Jul 2021
FARMINGTON HILLS, Mich., July 09, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely o
OCUP Stock Price Increases Over 30%: Why It Happened
09:55am, Wednesday, 30'th Jun 2021
The stock price of Ocuphire Pharma Inc (NASDAQ: OCUP) increased by over 30% during intraday trading this morning. This is why it happened.
Ocuphire Pharma Stock Surges After Nyxol Combo Treatment Meets Study Endpoints In Presbyopic Patients
08:00am, Wednesday, 30'th Jun 2021
Ocuphire Pharma Inc (NASDAQ: OCUP) announced data from the VEGA-1 Phase 2 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects. Pr
Ocuphire's VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
07:15am, Wednesday, 30'th Jun 2021
Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol ® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near vision
Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent
01:55pm, Thursday, 17'th Jun 2021
Processa Pharmaceuticals Inc (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ: OCUP) to in-license RX-3117. RX-3117 is an oral anticancer agent with an impro
